Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

45.21 +0.14 (+0.32%)
Streaming Delayed Price Updated: 3:32 PM EDT, May 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gsk Plc ADR

< Previous 1 2 3 4 5 6 7 8 9
...
28 29 Next >
Penny Stock Detox: 3 Stocks to Buy for Multibagger Returns Instead
Don't fall for the siren song of penny stocks. Rather, fill your portfolio with companies that have a proven track record of success. 
Via InvestorPlace
Top Wall Street Analysts Flag US Market Concentration Anxiety, Advise Investors To Adopt 'Barbell Approach'
Goldman Sachs urges investors to diversify geographically due to high concentration in US tech stocks, with Japan, healthcare, and European GRANOLAS highlighted as promising markets. 
Via Benzinga
3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise
Discover the pivotal roles of cancer-fighting biotech stocks that are advancing cancer research and subsequently, their financial growth. 
Via InvestorPlace
GSK's Withdrawn Multiple Myeloma Drug Shows Encouraging Combination Therapy Data In Second Late-Stage Study
GSK's DREAMM-8 trial reveals positive interim results for Blenrep combo in relapsed multiple myeloma. Improved progression-free survival and overall survival trend observed. 
Via Benzinga
Looking Into GSK's Recent Short Interest
Via Benzinga
Recap: GSK Q4 Earnings
Via Benzinga
Injectable HIV Treatment By ViiV Healthcare Outperforms Oral Therapy, Interim Data Shows
Findings from ViiV Healthcare's LATITUDE trial on long-acting HIV treatment. Cabenuva demonstrates superior efficacy in viral load suppression compared to daily oral therapy. Key secondary endpoints... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Pfizer/GSK-Backed ViiV Healthcare's HIV Drug Associated With Increased Resistance, WHO Report Says
WHO's latest HIV Drug Resistance Report reveals trends in drug resistance. Discover insights on dolutegravir's impact, challenges in HIVDR monitoring, and recommendations for standardized... 
Via Benzinga
Crucial Battle Over Healthcare Mandates: Biden Administration Defends Preventive Care Coverage Amidst Legal Challenges
The Biden administration wants insurers to cover preventive care, facing opposition from businesses led by Braidwood Management. 
Via Benzinga
Advil Maker Haleon Expects Higher 2024 Revenue After Strong 2023 Earnings, Stock Soars
Haleon reports FY 2023 revenue growth of 4.1% to £11.3 billion ($14.03 billion), missing consensus. Adjusted operating profit rises 10.4% to £2.55 billion. CEO Brian McNamara outlines solid financial... 
Via Benzinga
GSK Settles Another California Lawsuit On Heartburn Drug Zantac Causing Cancer, Second Within A Month
GSK settles California lawsuits over Zantac cancer allegations. Confidential agreements reached, cases dismissed. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields
A group of stocks, which Goldman Sachs dubbed the "Granolas," accounted for 50% of gains of the Stoxx Europe 600 Index for the past year. 
Via Benzinga
GSK's Gepotidacin Oral Antibiotic Non-Inferior To Commonly Used Muscle-Injected Antibiotic Combo For Sexually Transmitted Infection
Results from GSK's EAGLE-1 phase 3 trial on gepotidacin, an oral antibiotic for uncomplicated urogenital gonorrhea. Non-inferior to leading treatment, it offers a potential solution amid rising... 
Via Benzinga
3 Undervalued Small-Cap Stocks to Add to Your Must-Buy List
Undervalued small-cap stocks are great for investors seeking options for upside potential, typically at a cheap share price. 
Via InvestorPlace
Why Range-Bound Moderna Could Get A Boost On Its Fourth-Quarter Report
The company unexpectedly came in with fourth-quarter earnings that beat projections. 
Via Investor's Business Daily
Moderna Stock Q4 Earnings Preview: RSV mRNA Vaccine Scrutiny, Diminishing Spikevax Revenue, FDA Approval In Focus
Moderna reports Q4 earnings on Feb. 22. Analysts expect $2.53B in revenue. Stock has faced challenges but potential for recovery with COVID-19 vaccine and FDA approval in 2024. 
Via Benzinga
Exposures COVID-19 Product Safety
3 Low-Priced Dividend Stocks With Solid Fundamentals & Growth
Solid dividend stocks with good growth outlooks can deliver high profits for investors and should become more popular as interest rates drop. 
Via InvestorPlace
Dividend Income Update January 2024
It’s dividend income update time. One of my favorite times of the month as I get to review my previous month of passive income received from my dividend income portfolio 
Via Talk Markets
Why Is Moderna Stock Trading Lower Today?
Moderna long term data indicates a faster decline in efficacy for its RSV vaccine than the RSV vaccines from GSK and Pfizer. 
Via Benzinga
Jim Cramer Expects Drugmaker Stock To Go 'Even Higher,' As For Kroger: 'What The Heck Is Going On?'
On CNBC’s "Mad Money Lightning Round," Jim Cramer believes in GSK plc (NYSE: GSK). 
Via Benzinga
The 7 Best Healthcare Stocks to Invest In for Big Gains in 2024
Invest in the future with healthcare stocks 2024; offering a blend of market stability and cutting-edge medical advancements. 
Via InvestorPlace
Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations
The Inflation Reduction Act's impact on drug prices. Medicare challenges pharmaceutical costs, offering relief to seniors and addressing the soaring prices in the U.S. healthcare system. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Novavax's Malaria Vaccine Gets WHO Prequalification, Has Potential Of Being An Affordable Option
Novavax's R21/Matrix-M malaria vaccine, with 75% efficacy in seasonal areas. Affordable at $3 per dose, it outshines GSK's vaccine. Global rollout expected mid-2024. 
Via Benzinga
Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review
The Dow led the major indexes higher. Big techs diverged on results. 
Via Investor's Business Daily
Topics Economy Stocks
Exposures Interest Rates US Equities
What's Going On With GSK Stock Today?
GSK settles U.S. Zantac lawsuit, avoiding trial. Confidential settlements reinforce commitment to legal efficiency. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Teva Sinks On Lackluster Profit Outlook Despite Walloping Quarterly Projections
Teva Pharmaceutical easily beat fourth-quarter views, but its 2024 profit guidance left something to be desired. 
Via Investor's Business Daily
GSK Upgrades Long-Term Outlook After Q4 Performance, Shingrix Vaccine And Newly Launched RSV Vaccine Shine
GSK's robust Q4 performance with a 21% YoY increase in adjusted operating profit. Arexvy vaccine sales hit £1.2B in 2023. Outlook for 2024, with 5%-7% sales growth and upgraded long-term projections. 
Via Benzinga
Nasdaq Futures Plummet As Alphabet, AMD Disappointments Sour Sentiment; Spotlight Shifts To Fed Statement, Powell's Presser
The record run of the market faces risk as the big tech earnings season got off to a negative start, casting cloud on profit outlook. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Earnings Scheduled For January 31, 2024
Companies Reporting Before The Bell • Novartis (NYSE:NVS) is likely to report quarterly earnings at $1.68 per share on revenue of $11.56 billion. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
28 29 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.